BR9711734A - Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila - Google Patents

Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila

Info

Publication number
BR9711734A
BR9711734A BR9711734A BR9711734A BR9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A
Authority
BR
Brazil
Prior art keywords
alpha
monochlorochloride
metäxiimino
azabicyclo
alfa
Prior art date
Application number
BR9711734A
Other languages
English (en)
Portuguese (pt)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beckman Corp filed Critical Smithkline Beecham Plc
Publication of BR9711734A publication Critical patent/BR9711734A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9711734A 1996-09-12 1997-09-08 Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila BR9711734A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (1)

Publication Number Publication Date
BR9711734A true BR9711734A (pt) 1999-08-24

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711734A BR9711734A (pt) 1996-09-12 1997-09-08 Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila

Country Status (22)

Country Link
EP (1) EP0929301A2 (enrdf_load_stackoverflow)
JP (1) JP2001500150A (enrdf_load_stackoverflow)
KR (1) KR20000036039A (enrdf_load_stackoverflow)
CN (2) CN1235544A (enrdf_load_stackoverflow)
AR (1) AR008176A1 (enrdf_load_stackoverflow)
AU (1) AU724086B2 (enrdf_load_stackoverflow)
BR (1) BR9711734A (enrdf_load_stackoverflow)
CA (1) CA2265661A1 (enrdf_load_stackoverflow)
CO (1) CO5031291A1 (enrdf_load_stackoverflow)
CZ (1) CZ83299A3 (enrdf_load_stackoverflow)
GB (1) GB9619074D0 (enrdf_load_stackoverflow)
HU (1) HUP9904401A3 (enrdf_load_stackoverflow)
ID (1) ID19589A (enrdf_load_stackoverflow)
IL (1) IL128781A0 (enrdf_load_stackoverflow)
MA (1) MA24359A1 (enrdf_load_stackoverflow)
NO (1) NO991194L (enrdf_load_stackoverflow)
NZ (1) NZ334268A (enrdf_load_stackoverflow)
PE (1) PE2499A1 (enrdf_load_stackoverflow)
PL (1) PL332074A1 (enrdf_load_stackoverflow)
TR (1) TR199900505T2 (enrdf_load_stackoverflow)
WO (1) WO1998010762A2 (enrdf_load_stackoverflow)
ZA (1) ZA978133B (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
CA2323177A1 (en) 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CA2520813C (en) * 2003-04-25 2009-10-27 Mitsubishi Pharma Corporation Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
ATE339192T1 (de) * 2003-05-14 2006-10-15 Eurand Pharmaceuticals Ltd Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
KR20070050081A (ko) 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
BRPI0513847A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
WO1998010762A3 (en) 1998-06-04
CZ83299A3 (cs) 1999-08-11
MA24359A1 (fr) 1998-07-01
KR20000036039A (ko) 2000-06-26
WO1998010762A2 (en) 1998-03-19
ID19589A (id) 1998-07-23
CN1235544A (zh) 1999-11-17
NO991194D0 (no) 1999-03-11
PE2499A1 (es) 1999-03-24
CN1446535A (zh) 2003-10-08
JP2001500150A (ja) 2001-01-09
AU4128897A (en) 1998-04-02
HUP9904401A3 (en) 2001-03-28
PL332074A1 (en) 1999-08-30
CO5031291A1 (es) 2001-04-27
AU724086B2 (en) 2000-09-14
EP0929301A2 (en) 1999-07-21
NO991194L (no) 1999-03-11
AR008176A1 (es) 1999-12-09
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
CA2265661A1 (en) 1998-03-19
NZ334268A (en) 2000-10-27
TR199900505T2 (enrdf_load_stackoverflow) 1999-06-21
GB9619074D0 (en) 1996-10-23
ZA978133B (en) 1999-04-12

Similar Documents

Publication Publication Date Title
EE9900540A (et) Omeprasooli ravimvorm
IS5721A (is) Pýróló [2,3-dl]pírimídín efnasambönd
FI945621L (fi) Säädetysti vapauttava valmiste
BR9706897B1 (pt) forma de dosagem farmacêutica.
DE69804995D1 (de) Zyklonabscheider
EE04293B1 (et) Stabiilsed lüofiliseeritud ravimvormid
GB9823101D0 (en) Pharmaceutically active compounds
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
IS5344A (is) 2-Amínópýridín sem innihalda sambrædda hringtengihópa sem NOS latar
DK0891978T3 (da) 5H-Thiazol(3,2-a)pyrimidinderivativer
BR9711734A (pt) Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila
ATE321784T1 (de) Pthrp analogen
NO20002451D0 (no) Kondenserte pyrazinforbindelser
IS4848A (is) Lyfjafræðilega gagnleg efnasambönd
GB9823102D0 (en) Pharmaceutically active compounds
ZA977807B (en) New pharmaceutically active compounds.
PL340372A1 (en) Novel 3,6x-hemiketals of 9a-azalydes class
DE59804098D1 (de) Verdampferanordnung
PT964867E (pt) Antagonistas da taquicinima
NO995033D0 (no) 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
EE04318B1 (et) Parendatud toimega LHRH antagonistid
NO995035D0 (no) 5,6,7-trisubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
ID16434A (id) Senyawa-senyawa 1,4-dihidropiridin
ZA977808B (en) New pharmaceutically active compounds.
DE69915055D1 (de) Antitumorale 1,5-diazaanthraquinone

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.